189 related articles for article (PubMed ID: 24901262)
1. Effects of polyquaternium- and benzalkonium-chloride-preserved travoprost on ocular surfaces: an impression cytology study.
Sezgin Akçay Bİ; Güney E; Bozkurt TK; Topal CS; Akkan JC; Ünlü C
J Ocul Pharmacol Ther; 2014 Sep; 30(7):548-53. PubMed ID: 24901262
[TBL] [Abstract][Full Text] [Related]
2. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
3. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
[TBL] [Abstract][Full Text] [Related]
4. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
5. Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.
Kumar S; Singh T; Ichhpujani P; Vohra S
Rom J Ophthalmol; 2019; 63(3):249-256. PubMed ID: 31687627
[No Abstract] [Full Text] [Related]
6. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
11. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination.
Brignole-Baudouin F; Riancho L; Liang H; Nakib Z; Baudouin C
J Ocul Pharmacol Ther; 2011 Jun; 27(3):273-80. PubMed ID: 21410334
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
[TBL] [Abstract][Full Text] [Related]
13. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
Liang H; Brignole-Baudouin F; Pauly A; Riancho L; Baudouin C
Adv Ther; 2011 Apr; 28(4):311-25. PubMed ID: 21424577
[TBL] [Abstract][Full Text] [Related]
14. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
15. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
[TBL] [Abstract][Full Text] [Related]
17. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells.
Ammar DA; Kahook MY
Mol Vis; 2011; 17():1806-13. PubMed ID: 21750606
[TBL] [Abstract][Full Text] [Related]
18. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
19. Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.
Muz OE; Dagdelen K; Pirdal T; Guler M
Int Ophthalmol; 2021 Nov; 41(11):3825-3835. PubMed ID: 34263385
[TBL] [Abstract][Full Text] [Related]
20. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
